{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:30Z","timestamp":1791559470922,"version":"4.3.4"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced hemolytic anemia (DIHA) is a rare but significant condition characterized by the premature destruction of red blood cells (RBCs) triggered by certain medications. Ceftriaxone, a commonly used antibiotic, has been linked to DIHA, presenting diagnostic challenges due to its diverse clinical manifestations. This study examines three cases of DIHA caused by ceftriaxone therapy at our center. The patients presented with symptoms such as fatigue, jaundice, and dark urine following ceftriaxone therapy. Laboratory tests indicated hemolytic anemia with decreased hemoglobin, elevated lactate dehydrogenase, and positive direct antiglobulin tests. Immunohematological workups confirmed ceftriaxone-induced antibodies targeting RBCs and guided management strategies, including discontinuation of ceftriaxone, supportive therapy, and corticosteroids. Timely diagnosis and collaboration between clinicians and laboratory specialists are crucial for optimal patient outcomes.<\/jats:p>","DOI":"10.4103\/ajts.ajts_38_24","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T06:29:49Z","timestamp":1724826589000},"page":"345-349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling the complexity: Case reports of drug-induced hemolytic anemia due to ceftriaxone"],"prefix":"10.4103","volume":"18","author":[{"given":"Anshika","family":"Yadav","sequence":"first","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20241224","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21307\/immunohematology-2019-098","article-title":"Drug-induced immune hemolytic anemia: The last 30 years of changes","volume":"30","author":"Arndt","year":"2014","journal-title":"Immunohematology"},{"key":"R2-20241224","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21307\/immunohematology-2019-100","article-title":"Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: Some interesting findings since 2007","volume":"30","author":"Garratty","year":"2014","journal-title":"Immunohematology"},{"key":"R3-20241224","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/trf.15151","article-title":"The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis","volume":"59","author":"Quintanilla-Bord\u00e1s","year":"2019","journal-title":"Transfusion"},{"key":"R4-20241224","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2020001726","article-title":"Bendamustine-induced immune hemolytic anemia: A case report and systematic review of the literature","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv"},{"key":"R5-20241224","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/trf.15226","article-title":"Etoricoxib-induced immune hemolytic anemia: First case presenting acute kidney failure","volume":"59","author":"Burgos","year":"2019","journal-title":"Transfusion"},{"key":"R6-20241224","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/trf.16360","article-title":"Serologic characteristics of oxaliplatin antibodies in 15 patients with drug-induced immune hemolytic anemia","volume":"61","author":"Nguyen","year":"2021","journal-title":"Transfusion"},{"key":"R7-20241224","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21307\/immunohematology-2019-102","article-title":"How we investigate drug-induced immune hemolytic anemia","volume":"30","author":"Leger","year":"2014","journal-title":"Immunohematology"},{"key":"R8-20241224","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40199-020-00386-1","article-title":"Bosentan-induced immune hemolytic anemia in 17 years old man. A case report","volume":"29","author":"Afra","year":"2021","journal-title":"Daru"},{"key":"R9-20241224","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-019-02773-3","article-title":"Pharmacokinetics of cefoperazone\/sulbactam in plasma and cerebrospinal fluid in patients with intraventricular hemorrhage after external ventricular drains","volume":"76","author":"Meng","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-20241224","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/jac\/dky323","article-title":"Comparison of empirical therapy with cefoperazone\/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae","volume":"73","author":"Su","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R11-20241224","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3389\/fphar.2019.01342","article-title":"Hemolytic anemia and reactive thrombocytosis associated with cefoperazone\/sulbactam","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Asian Journal of Transfusion Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_38_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:23Z","timestamp":1786647623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_38_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ajts.ajts_38_24","relation":{},"ISSN":["0973-6247","1998-3565"],"issn-type":[{"value":"0973-6247","type":"print"},{"value":"1998-3565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-02-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}